[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ptsd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ptsd":595},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,129,0,25,[9,46,74,97,117,142,160,183,210,237,256,285,310,332,352,370,389,410,437,458,479,502,528,556,576],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100585485",false,"NCT06902974","Psilocybin-Assisted Therapy for Sexual Assault-Related PTSD","A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD)","SUN004","Inclusion Criteria:\n\n* Cisgender women who are at least 18 years old.\n* Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for current PTSD secondary to sexual assault (i.e., index trauma is sexual assault that occurred 6 or more months in the past).\n* CAPS-5 score of 25 or higher at Baseline.\n* Are able to swallow pills.\n* Are willing to be driven home after the Dosing Session with a family member or caregiver or trusted transportation.\n* Are able to complete all protocol-required assessment tools without any assistance or alteration to the copyrighted assessments, and to comply with all study visits.\n* If able to become pregnant (i.e., with uterus and associated reproductive organs, fertile, following menarche and until becoming post-menopausal unless permanently sterile), must have a highly sensitive negative pregnancy test at study entry and prior to the Dosing Session, and must agree to use adequate birth control through 10 days after the Dosing Session if sexually active with a biologically male partner. Adequate birth control methods include intrauterine device (IUD), injected, implanted, intravaginal, or transdermal hormonal methods, abstinence, oral hormones plus a barrier contraception, vasectomized sole partner, or double barrier contraception. Two forms of contraception are required with any barrier method or oral hormones (i.e. condom plus diaphragm, condom or diaphragm plus spermicide, oral hormonal contraceptives plus spermicide or condom).\n* Must agree to inform the clinical investigators within 48 hours of any medical conditions and procedures.\n* Are proficient in speaking and reading English.\n* Agree to have all clinic visit sessions recorded to audio and\u002For video. Participants may opt out of the data analysis of the recordings.\n* Agree to the following lifestyle modifications: a light breakfast 2 to 3 hours before dosing is permitted, however, participants will refrain from caffeine and nicotine 2 hours prior to dosing sessions and at least 6 hours after dosing, abstain from alcohol for 24 hours prior to dosing, not enroll in any other interventional clinical studies during the duration of the study, be driven home after the Dosing Session, and commit to medication dosing, therapy, and study procedures.\n* Agree to refrain from beginning new medication and\u002For psychotherapy treatment.\n* Continued treatment with SSRIs will be permitted if participants have been on a stable dose for 3 months or longer prior to enrollment. However, participants must be tapered off of monoamine oxidase inhibitors (MAOIs) prior to dosing.\n\nIn addition, participants may remain in stable (\\> 3 months) psychotherapy.\n\n* May have well-controlled hypertension that has been successfully treated with anti-hypertensive medicines.\n* May have asymptomatic Hepatitis C virus (HCV) that has previously undergone evaluation and treatment as needed.\n* May have alcohol or substance use disorder if participant is not in withdrawal or requiring detox. Participants must have a plan, agreed upon by the principal investigator or designated physician, to reduce use of alcohol or other substances and to manage symptoms without self-medicating. Enrollment will require that, in the judgment of the principal investigator or designated physician, the plan for decreasing substance use is realistic and has a good chance of succeeding in order to prevent substance use from impacting the safety or efficacy of the investigational treatment.\n* May have a history of or current Diabetes Mellitus (Type 2) if additional screening measures rule out underlying cardiovascular disease, if the condition is judged to be stable on effective management, and with approval by the principal investigator or designated physician.\n* May have hypothyroidism if taking adequate and stable thyroid replacement medication.\n\nExclusion Criteria:\n\n* Male\n* Condition impairing oral intake or digestive absorption.\n* Are not able to give adequate informed consent.\n* Significant suicide risk as defined by suicidal ideation with intend and a plan as endorsed on items 5 on the C-SSRS within the past 3 months\n* Have any current problem which, in the opinion of the principal investigator or designated physician, might interfere with participation.\n* Would present a serious risk to others as established through clinical interview and contact with treating therapist.\n* Have a history of, or a current primary, schizophrenia, schizoaffective disorder or any form of psychotic disorder, major depressive disorder with psychotic features, bipolar affective disorder type 1, or personality disorders.\n* Require ongoing concomitant therapy with a psychiatric medication with exceptions described below (see Section 6.6).\n* Have received Electroconvulsive Therapy (ECT) within 12 weeks of enrollment.\n* Have evidence or history of recent stroke (\\\u003C 6 months from signing of ICF), recent myocardial infarction (\\\u003C 6 months from signing of ICF), or clinically significant arrhythmia within 1 year of signing the ICF.\n* Have evidence or history of significant (controlled or uncontrolled) hematological, endocrine, cerebrovascular, cardiovascular, coronary, pulmonary, renal, gastrointestinal, immunocompromising, or neurological disease, including seizure disorder, or any other medical disorder judged by the investigator to significantly increase the risk of psilocybin administration.\n* Have uncontrolled hypertension using the standard criteria of the American Heart Association (values of 140\u002F90 milligrams of Mercury \\[mmHg\\] or higher).\n* Abnormal and clinically significant results on vital signs, ECG, or laboratory tests at screening and baseline\n* Have symptomatic liver disease.\n* Are pregnant, nursing, or able to become pregnant and are not practicing an effective means of birth control if sexually active with a biologically male partner.\n* Have hypersensitivity to any ingredient of the study drug.\n* Positive urine drug screen for illicit drugs or drugs of abuse prior to the Dosing Session. Any positive urine drug test will be reviewed with participants to determine the pattern of use and eligibility will be determined at the investigator's discretion.\n* Current enrollment in any investigational drug or device study or participation in such within 30 days of screening.\n* Other personal circumstances and behavior judged to be incompatible with establishment of rapport or safe exposure to psilocybin or completion of clinical study procedures (e.g., active participation in legal proceedings).","FEMALE","18 Years",{"count":20,"type":21},70,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","A Phase 2, Open-Label Study to explore the efficacy, safety, and tolerability of psilocybin-assisted therapy in women with sexual assault-related Posttraumatic Stress Disorder (PTSD).",[27,28],"Post Traumatic Stress Disorder","PTSD",[28,30,31,32],"sexual assault","psilocybin","posttraumatic stress disorder","RECRUITING","2026-06-30",{"date":36,"type":37},"2026-07-01","ACTUAL",{"date":39,"type":37},"2026-05-23",{"date":41,"type":21},"2028-05",{"name":43,"class":44},"Sunstone Medical","OTHER",1,{"id":47,"slug":4,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":52,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100474444","NCT05457985","Testing Adaptive Interventions to Improve Posttraumatic Stress Disorder Treatment Outcomes in Federally Qualified Health Centers","Testing Adaptive Interventions to Improve Posttraumatic Stress Disorder (PTSD) Treatment Outcomes in Federally Qualified Health Centers","Inclusion Criteria:\n\n* Receive care at a participating federally qualified health center (FQHC)\n* Have a Posttraumatic Stress Disorder checklist (PCL-5) score greater or equal (≥) to 33\n* Own a mobile device that can be used for the PTSD Coach App\n* Have had psychotropic medication stability for at least 4 weeks\n\nExclusion Criteria:\n\n* Severe cognitive impairment that in the judgment of the investigators makes it unlikely that the participant can adhere to the study regimen (as evidenced by confusion, inability to track discussion or answer questions, or other clear and significant indicators of cognitive impairment)\n* High risk of suicide (defined as meeting criteria for Action Step 3 on the Participant Suicide Risk Screening form\n* Severe alcohol or substance use disorder (moderate-severe alcohol use disorder on Alcohol Use Disorders Identification Test (AUDIT) (scores ≥ 15) or high risk on National Institute on Drug Abuse Quick Screen (scores ≥ 27))\n* Active psychosis or unmanaged bipolar disorder\n* Unstable housing\n* Current engagement in a trauma-focused behavioral treatment (such as Prolonged Exposure or Cognitive Processing Therapy).\n* Patients who do not speak English will be excluded for logistical reasons.","ALL",{"count":54,"type":21},430,[56],"NA","This trial is being completed to develop a stepped-care talk therapy model for patients with PTSD. Specifically, this study is testing whether beginning with one type of therapy is better than beginning with another type of therapy, and whether moving to a different therapy after four sessions is more helpful than staying with the same therapy, depending on how well it is working.\n\nThe central hypothesis is that beginning with a low- or medium-intensity PTSD intervention and then titrating intensity based on early indications of response will result in clinically significant PTSD symptom reduction with parsimony of resources.",[28],[60,61,62,63,64],"Prolonged Exposure for Primary Care","Mobile device","Clinician Supported PTSD Coach App","PTSD symptoms","Prolonged Exposure\u002FPE","2026-06-29",{"date":36,"type":37},{"date":68,"type":37},"2022-06-23",{"date":70,"type":21},"2027-09-30",{"name":72,"class":44},"University of Michigan",13,{"id":75,"slug":4,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":52,"minAge":18,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":45},"100645264","NCT07680517","Examining the Efficacy of Short-Term Intensive PTSD Treatment on Psychological and Cognitive Impairment Symptoms","Inclusion Criteria:\n\n-Treatment-seeking military personnel (i.e., any assigned or aligned JSOC personnel) who meet diagnostic criteria for PTSD or subthreshold PTSD (i.e., meeting diagnostic threshold for 3 of 4 symptom criteria who are (1) 18 years of age or older; (2) current diagnosis of PTSD or subthreshold PTSD (i.e. meeting diagnostic criteria for 3 of 4 symptom criteria, assessed using the DIAMOND); (3) current military personnel; (4) ability to speak and understand the English language; and (5) ability to complete the informed consent process\n\nExclusion Criteria:\n\n* (1) substance use disorder requiring medical management; (2) imminent suicide risk warranting inpatient hospitalization or suicide-focused treatment; and (3) impaired mental status that precludes the ability to provide informed consent (e.g., intoxication, psychosis, mania).",{"count":80,"type":21},120,[56],"Our long-term goal is to provide rapid and sustained reductions of trauma and cognitive-related symptoms among Special Operations personnel with PTSD or subthreshold PTSD. The primary objective of this project is to examine the effectiveness of massed PTSD treatment (i.e., CPT and EMDR) in \"real-world\" military settings. CPT and EMDR are both empirically supported psychotherapies for PTSD. To accomplish this objective, we will enroll military personnel meeting diagnostic criteria for PTSD or subthreshold PTSD (i.e., meeting threshold levels for 3 of 4 symptom criteria).",[28,84],"Cognitive Performance",[28,86,87],"CPT","Military","2026-06-25",{"date":90,"type":37},"2026-07-02",{"date":92,"type":37},"2026-04-01",{"date":94,"type":21},"2028-08",{"name":96,"class":44},"Ohio State University",{"id":98,"slug":4,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":52,"minAge":18,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":22,"phases":104,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":45},"100538044","NCT06285708","Enhancing the Effectiveness of Prolonged Exposure Among Suicidal Individuals With PTSD","Inclusion Criteria:\n\n* Current diagnosis of PTSD or subthreshold PTSD; ability to speak and understand the English language; and ability to complete the informed consent process.\n\nExclusion Criteria:\n\n* Substance use disorder requiring medical management; imminent suicide risk warranting inpatient hospitalization or suicide-focused treatment; and impaired mental status that precludes the ability to provide informed consent (e.g., intoxication, psychosis, mania).",{"count":103,"type":21},100,[56],"The long-term goal of this study is to reduce suicidal thoughts and behaviors among treatment-seeking individuals who also have posttraumatic stress disorder (PTSD). Prolonged exposure (PE) and crisis response plan (CRP) have demonstrated empirical support for reducing suicide attempts as compared to treatment as usual. However, no studies to date have assessed their effectiveness when used in combination. In light of this knowledge gap, the primary objective of this study will be to test the effectiveness of PE augmented with CRP as compared to PE with care as usual (self-guided treatment plan), an active comparator, for the reduction of suicide ideations and attempts for individuals with comorbid PTSD.",[28,107,108,109],"Suicidal Ideation","Suicide, Attempted","Trauma, Psychological","2026-06-24",{"date":65,"type":37},{"date":113,"type":37},"2024-02-26",{"date":115,"type":21},"2027-06",{"name":96,"class":44},{"id":118,"slug":4,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":52,"minAge":18,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":127,"conditions":128,"keywords":130,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":45},"100545753","NCT06386003","Psilocybin-Assisted Cognitive Processing Therapy for Chronic PTSD","Psilocybin-Assisted Massed Cognitive Processing Therapy for Chronic Posttraumatic Stress Disorder: An Open-label Trial","Inclusion Criteria:\n\n1. Meet Diagnostic and Statistical Manual-5th edition (DSM-5) criteria for current PTSD with a duration of 6 months or longer assessed by study psychiatrist;\n2. Have a Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) score of 50 or higher, indicating moderate to severe PTSD symptoms;\n3. Are willing to refrain from taking any psychiatric medications during the study period.\n\nExclusion Criteria:\n\n1. Are pregnant or nursing, or are women of child bearing potential who are not practicing an effective means of birth control;\n2. Have a history of or a current primary diagnosis of psychotic disorder, schizophrenia, delusional disorder, borderline personality disorder, schizoaffective disorder, bipolar disorder or, dissociative identity disorder;\n3. Have evidence or history of coronary artery disease or cerebral or peripheral vascular disease, hepatic disease with abnormal liver enzymes, or any other medical disorder judged by the investigator to significantly increase the risk of psilocybin administration;\n4. Have hypertension using the standard criteria of the American Heart Association (values of 140\u002F90 or higher assessed on three separate occasions;\n5. History of seizure disorder;\n6. Uncontrolled insulin-dependent diabetes;\n7. Recent stroke, intracranial or subarachnoid hemorrhage (\\\u003C 1 year from signing of informed consent form \\[ICF\\]), recent myocardial infarction (\\\u003C 1 year from signing of ICF), clinically significant arrhythmia (\\\u003C 1 year from signing of ICF);\n8. Have liver disease with the exception of asymptomatic subjects with Hepatitis C who have previously undergone evaluation and successful treatment;\n9. Lifetime history of substance-induced psychosis;\n10. Lifetime history of substance use disorder with a hallucinogen;\n11. History of alcohol use disorder in the past 3 months.","65 Years",{"count":125,"type":21},15,[24],"This is an open-label trial evaluating feasibility, tolerability, safety and efficacy of psilocybin assisted cognitive processing therapy for chronic Posttraumatic Stress Disorder (PTSD).",[27,28,129],"Chronic PTSD",[27,131,132],"Psilocybin","Cognitive Processing Therapy","2026-06-22",{"date":135,"type":37},"2026-06-26",{"date":137,"type":21},"2026-06",{"date":139,"type":21},"2027-01",{"name":141,"class":44},"Unity Health Toronto",{"id":143,"slug":4,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":52,"minAge":18,"maxAge":147,"enrollmentInfo":148,"targetDuration":4,"studyType":22,"phases":150,"briefSummary":151,"conditions":152,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":158,"locationsCount":45},"100641178","NCT07658157","Exposure by Assessment: Effects of Daily AMQ-Based EMA of an Intrusive Trauma Memory in PTSD","Inclusion Criteria:\n\n* Adults aged 18-70\n* Posttraumatic stress disorder\n* intrusive symptoms.\n\nExclusion Criteria:\n\n* Psychotic or bipolar disorder\n* Heavy use of drugs or alcohol\n* Prominent personality disorder\n* Significant risk of harm to self or others\n* Current trauma-focused treatment\n* Reporting intrusions as thoughts only rather than as memories","70 Years",{"count":149,"type":21},50,[56],"Intrusive re-experiencing is a hallmark of PTSD. The study applies ecological momentary assessment (EMA) of participants' trauma memories (active group) vs. EMA of a neutral memory (control group) to test whether the active intervention can reduce intrusive symptoms severity and overal PTSD symptom severity in general.",[28],"2026-06-20",{"date":88,"type":37},{"date":156,"type":37},"2026-06-14",{"date":115,"type":21},{"name":159,"class":44},"Tel Aviv University",{"id":161,"slug":4,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":166,"sex":52,"minAge":18,"maxAge":123,"enrollmentInfo":167,"targetDuration":4,"studyType":22,"phases":169,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":174,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":45},"100644304","NCT07664631","Effects of Stimulant Medications in PTSD","SMP","Inclusion Criteria:\n\n* Age 18 - 65 years old\n* BMI 19-30 kg\u002Fm2\n* English fluency\n\nExclusion Criteria:\n\n* Individuals with current moderate or severe substance use disorder, no past stimulant or cocaine use disorder\n* Individuals with current acute or high risk of suicide or suicide attempt in past 6 months\n* Individuals with current psychotic or bipolar disorder\n* Individuals with past schizophrenia, schizoaffective disorder, psychotic bipolar disorder, stimulant or cocaine use disorder\n* Individuals with chronic (non-PRN) treatment with antipsychotic drug (except PRN quetiapine 25mg PO qHS) or D2 antagonist\n* Individuals with medications with significant PD or PK interactions\n* Individuals with current treatment with a stimulant medication\n* Individuals with court or legally mandated treatment\n* Individuals with unstable or untreated medical disorder that would increase the risk of serious side effects of study drug (unstable hypertension, tachycardia, cardiac arrhythmia, recent MI or stroke, clinically significant neuropsychiatric or neurological disorder)\n* Members of a vulnerable population\n* High blood pressure (\\>140\u002F90)\n* Women who are pregnant, breastfeeding, or planning to become pregnant",true,{"count":168,"type":21},40,[170],"PHASE1","While there have been advances in understanding post-traumatic stress disorder (PTSD) as a disorder and its biological features, unfortunately only one out of five traumatized persons with PTSD reach remission after cycling through evidence-based and\u002For FDA-approved medications. This is especially unfortunate given that people with PTSD are often from vulnerable populations, or those whose professions entail personal sacrifice. It is clear that new serotonergic antidepressants and atypical antipsychotics will not be sufficient to fix this gap, and new mechanisms of action need to be tested. In the current proposal, the investigators test the hypothesis that mixed amphetamine salts (brand name Adderall), FDA-approved for treating attention deficit hyperactivity disorder (ADHD), can improve PTSD outcomes.",[173,28,27],"Adderall","NOT_YET_RECRUITING","2026-06-18",{"date":110,"type":37},{"date":178,"type":21},"2026-09-15",{"date":180,"type":21},"2027-09-15",{"name":182,"class":44},"University of Chicago",{"id":184,"slug":4,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":52,"minAge":18,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":22,"phases":191,"briefSummary":192,"conditions":193,"keywords":196,"overallStatus":174,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":209},"100642569","NCT07645274","Improving Mental Healthcare Outcomes for Minoritized Veterans Through a Peer-led, Patient Navigation Program (PARTNER-MH 2.0)","PARTNER-MH","Inclusion Criteria:\n\n* Member of a racial or ethnic minoritized group\n* Veterans who are currently receiving or waiting to receive treatment in the outpatient mental health clinics or affiliated CBOCS at the study sites\n* Eligible participants must be:\n\n  * waiting to start treatment (e.g., Veterans who were referred to treatment, assigned a provider, or recommended a treatment option that includes either pharmacotherapy, psychotherapy, or both but have not yet started treatment at time of enrollment)\n* Veterans who are already receiving ongoing treatment - pharmacotherapy, individual, and\u002For group psychotherapy, but initiated treatment within 9 months of study enrollment date\n* Have a diagnosis of depression, anxiety, or PTSD\n* Not currently receiving peer services in the outpatient clinic\n\nExclusion Criteria:\n\n* Patients needing emergency psychiatric services of hospitalization due to suicidal ideation or recent suicide attempt (within past 2 months), have severe psychiatric symptoms (e.g., active psychosis), or a diagnosis of severe mental illness (e.g., schizophrenia)\n* Severe cognitive, hearing, or speech impairment (e.g., dementia, severe TBI)\n* Severe physical illness that impedes study participation\n* Recent hospitalization for substance use disorder (SUD) for the past 2 months or severe SUD symptoms based on the screen tools (AUDIC-C, DAST-10) that may require higher level of care and peer support",{"count":190,"type":21},268,[56],"The proposed project is a randomized controlled trial that seeks to test the effectiveness of a peer-facilitated, patient navigation program to improve mental healthcare experiences and outcomes for under-supported Veterans from diverse cultural backgrounds and communities. PARTNER-MH is a structured, telehealth-based intervention delivered by VHA peer specialists over a three-month period. It integrates two evidence-based care delivery models, peer support and patient navigation, and addresses three primary contributors to healthcare disparities: unmet social needs, low patient engagement in care, and unproductive patient-clinician communication. Findings from this study will support ongoing efforts to improve mental health services for all Veterans in the VHA.",[194,195,28],"Diagnoses of Depression","Anxiety",[197,195,198],"Depression","Post-traumatic stress disorder","2026-06-12",{"date":201,"type":37},"2026-06-16",{"date":203,"type":21},"2027-01-04",{"date":205,"type":21},"2031-12-31",{"name":207,"class":208},"VA Office of Research and Development","FED",2,{"id":211,"slug":4,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":166,"sex":52,"minAge":216,"maxAge":217,"enrollmentInfo":218,"targetDuration":4,"studyType":22,"phases":220,"briefSummary":221,"conditions":222,"keywords":226,"overallStatus":174,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":231,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":4},"100540003","NCT06311188","Exploring PTSD Symptoms, Barriers and Facilitators to Mindfulness","Exploring PTSD Symptoms, Barriers and Facilitators to Mindfulness-based Stress Reduction for Justice-Involved Black\u002FAfrican American Female Adolescents and Parents\u002FCaregivers","Inclusion Criteria:\n\n* Black girls aged 14-18\n* Black girls with a misdemeanor and\u002For felony charge in their lifetime\n* Positive PTSD screen (PC-PTSD score of 2 or more; if more than one JI BAFA are from the same family, the investigators will recruit the girl with the highest PTSD score)\n* Black girls report juvenile justice involvement within 12 months prior\n* Black girls live with a P\u002FC (mothers, fathers, and other caregivers\u002Flegal guardians) who will also participate in the study\n* Parents\u002FCaregivers nominated by the girls to participate in the study who are between the ages of 18 and 90 years of age\n* Legal\u002F social services providers \u002F educators who work with the population.\n\nExclusion Criteria:\n\n* Prisoners per the IRB definition\n* Black girls who are younger than 14 and older than 18\n* Severe cognitive delay so the youth cannot complete the assessment instruments, as measured using the Montreal Cognitive Assessment (MoCA)\n* Active psychosis requiring a greater level of care \\[Structured Clinical Interview for DSM Disorders (SCID)\\]. Screening for the study will take place prior to consent\u002Fassent of the study participants\n* Parents\u002FCaregivers who are not nominated by the girls to participate in the study who are not between the ages of 18 and 90 years of age\n* Legal\u002F social services providers \u002F educators who have been working with the population for less than three years.","14 Years","90 Years",{"count":219,"type":21},90,[56],"The purpose of this study is to investigate justice-involved Black\u002FAfrican American female adolescents' (JI BAFAs; N=35) self-reported outcomes: stress, posttraumatic stress disorder (PTSD), recidivism, etc., as well as their parents\u002Fcaregivers' (P\u002FCs; N=35) stress and pre- and post- intervention results along with their views of an adapted intervention.",[223,224,28,225],"Stress","Trauma","HPA",[227,228,229,230],"Nonrandomized trial","Black girls","Legal system involvement","Cortisol Biomarker",{"date":201,"type":37},{"date":233,"type":21},"2026-07-08",{"date":235,"type":21},"2027-01-31",{"name":72,"class":44},{"id":238,"slug":4,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":52,"minAge":18,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":22,"phases":244,"briefSummary":245,"conditions":246,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":45},"100537522","NCT06278922","Evaluating Signs of Safety: A Deaf-Accessible Therapy Toolkit for AUD and Trauma","Inclusion Criteria:\n\n* Self-identification as Deaf or hard-of-hearing\n* Proficiency in American Sign Language (ASL)\n* Age 18 years or older\n* Access to videoconferencing technology for informed consent and, if applicable, study therapy sessions\n* Access to online survey technology for study assessments\n* \"Problematic alcohol consumption, drinking behaviors, and alcohol-related problems\" on the AUD Identification Test (AUDIT), a 10-item screening measure developed by the World Health Organization that demonstrates good sensitivity and specificity in many populations (past-month referent time period; score ≥ 8 for men or ≥ 6 for women)\n* \"Subthreshold or full PTSD,\" on the PTSD Checklist for DSM-5 (PCL-5), a 20-item measure of PTSD symptoms reliably used to monitor symptom change (past-month referent time period; \"subthreshold\" = meets at least two DSM-5 diagnostic categories (B, C, D, and\u002For E) at moderate or high severity)\n\nExclusion Criteria:\n\n* Participation in concurrent formal psychotherapy (Note: Participants in all study conditions will be asked to refrain from concurrent formal psychotherapy. Participants who engage in formal psychotherapy outside of the research will be removed from the study at the point of treatment initiation. Outside treatment engagement will be queried at each assessment timepoint. If endorsed, the participant will be removed from the study at that timepoint, but data collected prior to treatment initiation will remain in the dataset. Aligning with the Seeking Safety model, Alcoholics Anonymous\u002FNarcotics Anonymous\u002FDual Recovery Anonymous attendance will be encouraged; attendance will be tracked as a potential outcome mediator.)\n* Members of the following special populations: Adults unable to consent; Individuals younger than 18 years; Prisoners; Pregnant women (Note: The investigators will not knowingly include pregnant women as participants; however, the investigators will not assess participants' pregnancy status.)",{"count":243,"type":21},144,[56],"The U.S. Deaf community - a group of more than one million Americans who communicate using American Sign Language (ASL) - experiences nearly triple the rate of lifetime problem drinking and twice the rate of trauma exposure compared to the general population. Although there are several treatments for alcohol use disorder (AUD) and posttraumatic stress disorder (PTSD) in hearing populations, none have been developed for or tested with Deaf clients. To address these barriers, the study team developed Signs of Safety, a Deaf-accessible therapy toolkit for treating AUD and PTSD. Their aims are to conduct a nationwide, virtual clinical trial to compare (1) Signs of Safety with (2) treatment as usual and (3) a no treatment control, to collect data on clinical outcomes, and to explore potential mediators and moderators of outcome.",[28,247],"Alcohol; Use, Problem",{"date":249,"type":37},"2026-06-15",{"date":251,"type":37},"2024-12-23",{"date":253,"type":21},"2028-11-30",{"name":255,"class":44},"University of Massachusetts, Worcester",{"id":257,"slug":4,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":11,"sex":52,"minAge":18,"maxAge":4,"enrollmentInfo":263,"targetDuration":4,"studyType":22,"phases":265,"briefSummary":266,"conditions":267,"keywords":270,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":45},"100641392","NCT07652645","Hybrid Dialectical Behavior Therapy for Veterans to Further Reduce Emotion Regulation Problems and Trauma Symptoms","REfreshment of Dialectical Behaviour Therapy for Veterans to Further Reduce Symptoms and Prevent Relapse of Post-traumatic Stress Disorder and Emotion Regulation Symptoms by Guided Self-Help","REFRESH","Inclusion Criteria:\n\n* Adult veteran (18 years or older), treated at Sinai Center, with knowledge of DBT\n* Primairy diagnosis of PTSD, determined with CAPS-5, resulting from war-related traumas\n* Stable for four weeks on their medication (type and doses)\n* Able to to do online homework assignments and communicate with their therapist via an eHealth platform\n* Dutch speaking\n\nExclusion Criteria:\n\n* Chronic psychosis (psychotic features as comorbidity from PTSD is allowed) or bipolar disorder type 1\n* IQ below 80 or cognitive disorders\n* Severe self-harming behaviour, such as auto-mutilation or suicidal ideations as main problem\n* Following day treatments or other intensive treatment for residual symptoms",{"count":264,"type":21},24,[56],"Around 10% of post-active veterans experience post-traumatic stress disorder (PTSD) many years post-mission. PTSD in veterans is frequently associated with challenges in emotion regulation, aggression, suicidality, and financial and psychosocial stress. In 2018, a 12-week clinical treatment programme, the Veterans Intensive Treatment Unit (VIBU), was developed for veterans experiencing these psychiatric symptoms, for whom conventional treatments had proven ineffective. The VIBU provides patients with trauma-focused and dialectical behaviour therapy (DBT). A recent study revealed that the VIBU was effective in reducing psychiatric symptoms. However, a recurrence of symptoms was observed in patients a few months after discharge. Consequently, an aftercare programme consisting of hybrid DBT is offered to consolidate and repeat the DBT skills and apply them in daily life.",[28,268,269],"Emotion Regulation Disorders","Substance Abuse",[271,28,272,273,274],"Emotional dysregulation","DBT","Hybrid DBT","Veterans","2026-06-11",{"date":277,"type":37},"2026-06-17",{"date":279,"type":37},"2026-06-01",{"date":281,"type":21},"2028-10",{"name":283,"class":284},"Arkin","INDUSTRY",{"id":286,"slug":4,"hasResults":11,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":11,"sex":52,"minAge":18,"maxAge":4,"enrollmentInfo":291,"targetDuration":4,"studyType":22,"phases":293,"briefSummary":294,"conditions":295,"keywords":297,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":303,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":45},"100610243","NCT07225049","Integrated PTSD and Chronic Pain Treatment","Pilot of an Integrated Treatment for Comorbid PTSD and Chronic Pain","Inclusion Criteria:\n\n* 18 years or older\n* English-speaking\n* Currently meets criteria for PTSD, assessed by the CAPS-5 (any trauma type) - Chronic pain, assessed by greater than or equal to 4 on a scale of 0-10 pain severity over the past 3 months\n* Medically stable at the time of study enrollment (chronic illness and disability does not prevent attendance of outpatient therapy sessions)\n* Stable on psychotropic medication for past 60 days\n* Agreed to not change current medication or pain-related treatments over the course of the study unless medically necessary\n* Must be located in the state of New York for virtual assessments and treatment sessions\n\nExclusion Criteria:\n\n* Lifetime diagnosis of schizophrenia, other psychotic disorder, or bipolar I disorder\n* Participation in concurrent evidence-based psychological treatment for PTSD or chronic pain during the past 3 months\n* Participants must not participate in an evidence-based psychological treatment for either PTSD or pain during the course of the study.\n* Moderate or severe substance use in the past 90 days\n* Cognitive impairment to the degree that the patient cannot provide informed consent or fill out assessment measures\n* Participants who in the PI's judgement pose a current homicidal or suicidal risk",{"count":292,"type":21},20,[56],"Posttraumatic stress disorder (PTSD) occurs in approximately 7% of adults in the general population. PTSD greatly impacts quality of life and often co-occurs with other conditions such as chronic pain. Individuals with co-morbid PTSD and chronic pain demonstrate higher PTSD symptoms and pain (as well as greater anxiety, depression, disability, and opioid use) compared to those with only one of those conditions. Gold standard treatments exist for both PTSD (e.g., Prolonged Exposure; PE) and chronic pain (e.g., Cognitive Behavioral Therapy for Chronic Pain; CBT-CP) and are generally offered sequentially (i.e., one at a time for the condition that is most prominent). Treating these conditions separately may overlook their interconnected nature, which may reduce efficacy and increase dropout. Thus, there is a need for an intervention to target both simultaneously, which may be more effective and efficient than treating conditions sequentially.\n\nThis is a single-arm pilot study to assess the feasibility and acceptability of an integrated treatment for adults with comorbid PTSD and chronic pain. The intervention consists of 12 90-minute virtual psychotherapy sessions scheduled twice per week. The treatment draws from modules in PE and CBT-CP including psychoeducation, exposure to feared\u002Favoided situations and activities, processing of exposures, behavioral activation, breathing and relaxation techniques, sleep hygiene, symptom monitoring, and structured homework assignments. Baseline and post-treatment assessments will be conducted.",[28,296],"Chronic Pain",[28,296,298,299,300,301,302],"Integrated Treatment","Comorbidity","Prolonged Exposure","CBT for Chronic Pain","Cognitive Behavioral Therapy for Chronic Pain",{"date":249,"type":37},{"date":305,"type":37},"2025-12-08",{"date":307,"type":21},"2027-08",{"name":309,"class":44},"Weill Medical College of Cornell University",{"id":311,"slug":4,"hasResults":11,"nctId":312,"briefTitle":313,"officialTitle":313,"acronym":4,"eligibilityCriteria":314,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":315,"targetDuration":4,"studyType":22,"phases":316,"briefSummary":317,"conditions":318,"keywords":320,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":325,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":329,"locationsCount":331},"100536234","NCT06262178","Parenting STAIR: Adapting a Trauma-Focused Parenting Intervention for Military-Connected Mothers and Their Children","Inclusion Criteria:\n\n1. Military-connected mother, defined as a mother who is either a female service member or veteran or female spouse of a service member or veteran;\n2. Has a child aged 2-10;\n3. Legal guardian of index child with legal and physical custody;\n4. Lifetime trauma exposure (Life Events Checklist (LEC-5); Adverse Childhood Experiences Questionnaire (ACE-Q));\n5. Screen positive for PTSD (defined as a PCL-5 score ≥32 or meeting ≥3 out of 4 DSM-5 symptom criteria \\[B, C, D, E\\] on the PCL-5), and\u002For depression (PHQ-9 score ≥8), and\u002For low parenting self-efficacy (PSOC score \\\u003C59);\n6. Able to speak and understand English or Spanish;\n7. Eligible to receive services at a Steven A. Cohen Military Family Clinic at Endeavors.\n\nExclusion Criteria:\n\n1. High risk for suicide (Ask Suicide-Screening Questions (ASQ));\n2. Current psychotic symptoms (DSM-5-TR Self-Rated Level 1 Cross-Cutting Symptom Measure Domain VII);\n3. Disability affecting communication, such as deafness;\n4. Index child with severe developmental disability;\n5. Severe substance or alcohol use (The Alcohol, Smoking and Substance Involvement Screening Test - Lite (ASSIST-Lite); Cannabis Use Disorder Identification Test-Short Form (CUDIT-SF)).",{"count":80,"type":21},[56],"The goal of this study is to assess Parenting STAIR Modular (PSTAIR-M), a promising and innovative intervention for military-connected mothers (MCM) who have experienced trauma and their young children (ages 2-10). PSTAIR-M aims to help mothers manage the strong feelings that sometimes happen after experiencing something scary or stressful, as well as to better connect with their children and manage their behavior effectively.\n\nThe main questions the study aims to answer are: 1) Does PSTAIR-M reduce maternal PTSD and\u002For depression symptoms?, and 2) Does PSTAIR-M improve parental functioning?\n\nResearchers will compare PSTAIR-M to treatment as usual (TAU) - other EBTs offered at participating study sites - to determine if PSTAIR-M is more effective in improving mental health and parenting.\n\nParticipants will: 1) attend 12-16 weekly, 1-hour online treatment sessions with their assigned clinicians, 2) complete three 1-hour online assessments administered by research staff, 3) engage with their child in three 15-30-minute online, observed play sessions, 4) have assessments and observed play sessions audio and video recorded.\n\nParticipants may also be invited to participate in an optional, 30-minute online one-on-one qualitative interview, which would be audio and video recorded and would cover participants' experiences with the intervention, the clinic sites, and their providers.",[28,197,319],"Parent-Child Relations",[28,197,321,322,323,319,324],"STAIR","PC-CARE","Parenting","Military Family",{"date":249,"type":37},{"date":327,"type":37},"2025-07-21",{"date":70,"type":21},{"name":330,"class":44},"New York University",3,{"id":333,"slug":4,"hasResults":11,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":11,"sex":52,"minAge":18,"maxAge":123,"enrollmentInfo":338,"targetDuration":4,"studyType":22,"phases":340,"briefSummary":341,"conditions":342,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":348,"leadSponsor":350,"locationsCount":125},"100631343","NCT07499440","Safety and Efficacy of HB-1 for Post-Traumatic Stress Disorder","Safety and Efficacy of HB-1 for PTSD: A Multi-center, Randomized, Double-Blind, Placebo-Controlled Study","Inclusion Criteria:\n\n* Male or female aged 18 to 65 years old, inclusive, at the time of informed consent.\n* Meets DSM-V Criteria for PTSD.\n* Minimum CAPS-5 score of at least 26 (based on the optimal diagnostic correspondence in the definitive CAPS-5 psychometric validation study).\n* Clinically stable on current medication and\u002For therapy regimen for at least 2 months, as determined by Investigator.\n* Willing to remain on current doses of other psychiatric medications throughout the length of the trial.\n* Willing and able to safely stop any medications that are contraindicated to be taken together with HB-1, as determined by Investigator.\n* Fluent in English.\n* Willing to take HB-1.\n* Willing and able to provide informed consent indicating an understanding of the requirements of the study and a willingness to comply with scheduled visits and all study procedures.\n* Female subjects must be surgically sterile (or have a monogamous partner who is surgically sterile) or be at least 2 years postmenopausal or agree to commit to use acceptable forms of birth control (defined as the use of an intrauterine device, a barrier method with spermicide, condoms, any form of hormonal contraceptives, or abstinence) for the duration of the study. Investigator shall use discretion and familiarity with subject's preferred and usual lifestyle to understand if reporting of abstinence may be trusted to achieve 100% effectiveness. Male subjects must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control (condoms with spermicide) for the duration of the study and for 4 months following the last dose of study treatment. Individuals who are involved exclusively in same-sex relationships are exempt from the birth control requirements but must agree to abide by the recommendations if they do engage in a heterosexual relationship.\n* Female subjects who are women of childbearing potential (WOCBP) must have a negative pregnancy test at Screening within 7 days of dosing with study treatment.\n\nExclusion Criteria:\n\n* Any ongoing concomitant disease, condition, or treatment that could interfere with the conduct of the study, or that would, in the opinion of the Investigator or Sponsor, pose an unacceptable risk to the participant in the study or interfere with the interpretation of study data.\n* Ongoing treatment with benzodiazepines (e.g. alprazolam, diazepam, clonazepam, lorazepam) or opiates (e.g., codeine, morphine) as assessed by clinical interview and urine toxicology testing.\n* Ongoing treatment with any medication that has a clinically significant drug-drug interaction with either telmisartan or verapamil, per the verapamil SR and telmisartan FDA labels and per standard drug interaction compendia. These include but are not limited to: Inhibitors or inducers of cytochrome P450 (CYP)3A4 (including certain β-hydroxy β-methylglutaryl-CoA \\[HMG-CoA\\] reductase inhibitors), Ivabradine, Antihypertensive Agents (including Beta Blockers), Antiarrhythmic Agents, Lithium, Carbamazepine, Rifampin, Phenobarbital, cyclosporin, theophylline, Inhalation Anesthetics, Neuromuscular Blocking Agents, Telithromycin, mTOR inhibitors as well as strong P-glycoprotein inhibitors (e.g., macrolides, ritonavir, itraconazole, ketoconazole, cyclosporin, ritonavir, and ivermectin).\n* Diagnosis of Severe Substance Use Disorder, Obsessive-Compulsive Disorder (OCD), Bipolar I, Bipolar II disorder, or Psychotic disorder (per SCID-V) or Borderline Personality Disorder (per Short-Bord).\n* Active suicidal ideation and behavior (Columbia-Suicide Severity Rating Scale \\[C-SSRS\\] score ≥ 4 at Screening, or who has made a serious suicide attempt in the last 3 months).\n* Severe uncontrolled cardiac disease within 6 months of Screening, including but not limited to: severe uncontrolled hypertension, hypotension (below 90\u002F60 mmHg); unstable angina; myocardial infarction (MI) or cerebrovascular accident (CVA).\n* Any clinically significant electrocardiogram (ECG) abnormalities at screening.\n* Inadequate hepatic function defined as total bilirubin \\> 1.5 × the upper limit of normal (ULN) ranges of each institution, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\> 3 × the ULN range of each institution.\n* Inadequate renal function defined as serum creatinine \\> 1.5 × the ULN range of each institution and\u002For estimated glomerular filtration rate (eGFR) \\\u003C 60 mL\u002Fmin.\n* Any clinically significant abnormalities in clinical laboratory assessments as assessed by the Investigator.\n* Already on treatment with either telmisartan or verapamil or both.\n* Documented contraindication to taking telmisartan or verapamil: (eg, prior drug allergy, Duchenne's muscular dystrophy, myasthenia gravis).\n* Pregnant or breastfeeding.\n* Participation in another current clinical trial or prior trial within the last three months.\n* Urinalysis evidence of exposure to substances that may interfere with HB-1 testing (per investigator discretion).",{"count":339,"type":21},200,[24],"The purpose of this study is to determine the safety and efficacy of HB-1, versus placebo in male and female adult patients aged 18 to 65 years, inclusive, with Post-Traumatic Stress Disorder (PTSD).",[28,343],"Mental Illness","2026-06-03",{"date":346,"type":37},"2026-06-04",{"date":137,"type":21},{"date":349,"type":21},"2027-10",{"name":351,"class":284},"HB BioTech, LLC",{"id":353,"slug":4,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":11,"sex":52,"minAge":18,"maxAge":4,"enrollmentInfo":358,"targetDuration":4,"studyType":22,"phases":359,"briefSummary":360,"conditions":361,"keywords":362,"overallStatus":174,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":45},"100452010","NCT05165940","Facilitating Transition to Recommended PTSD Treatment","Improving Care for Veterans by Understanding and Facilitating Transition to Recommended PTSD Treatment (CDA 21-194)","Inclusion Criteria:\n\n* Veteran\n* Diagnosed with PTSD as part of an intake assessment at the San Francisco Veterans Affairs Medical Center.\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Cognitive impairment that precludes comprehension of study materials\n* Active psychosis",{"count":168,"type":21},[56],"Cognitive processing therapy (CPT) and prolonged exposure therapy (PE) were widely disseminated as recommended posttraumatic stress disorder (PTSD) treatments. However, post-9\u002F11 Veterans with PTSD rarely initiate CPT or PE, especially as an initial treatment. Little research has explored the combinations and sequences of psychosocial and medication treatments that Veterans receive (\"treatment sequences\"). One common and understudied treatment sequence begins with stabilization treatment, which is designed to prepare Veterans for CPT or PE. There is a significant research gap in understanding how treatment sequence affects initiation of CPT or PE. The proposed research is an innovative, mixed-methods approach to assessing the impact of variability in treatment sequence, including stabilization treatment, on initiation of CPT or PE and applying this knowledge by developing a health services intervention that facilitates timely transition to CPT or PE. Research aims can improve PTSD treatment by increasing initiation of and reducing disparities in CPT\u002FPE.",[28],[28],{"date":364,"type":37},"2026-06-02",{"date":366,"type":21},"2026-08-01",{"date":368,"type":21},"2027-05-03",{"name":207,"class":208},{"id":371,"slug":4,"hasResults":11,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":11,"sex":52,"minAge":18,"maxAge":4,"enrollmentInfo":376,"targetDuration":4,"studyType":22,"phases":378,"briefSummary":380,"conditions":381,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":384,"completionDateStruct":385,"leadSponsor":387,"locationsCount":45},"100559905","NCT06570213","Evaluating The Efficacy Of Combined Cognitive Processing Therapy and Stellate Ganglion Blocks for PTSD","Evaluating The Efficacy Of Combined Cognitive Processing Therapy and Stellate Ganglion Blocks for PTSD: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Are 18 years or older\n* Are fluent in English\n* Have experienced a Criterion A traumatic event during their lifetime\n* Have a PTSD diagnosis verified via the Clinician Administered PTSD Scale for DSM-5\n* Have not previously received a Stellate Ganglion Block\n* Have a smartphone that they can use for the entire duration of the study\n* Are willing and able to receive 2 injections (SGB or placebo) 2 weeks apart at the Rush Pain Clinic\n* Are willing and able to participate in daily Cognitive Processing Therapy or Daily Monitoring over the course of one week\n* Are willing and able to complete self-report measures and clinician-rated assessments at multiple time points over the course of the study\n\nExclusion Criteria:\n\n* The traumatic event occurred in the past month\n* They are currently suicidal or homicidal (i.e., plan and intent)\n* They have unmanaged psychosis or mania\n* They have not been on a stable dose of psychotropic medication for at least one month by the time of the baseline assessment or are planning to change their medications within 3 months of starting their participation in the study\n* They have completed an evidence-based cognitive behavioral PTSD treatment (e.g., Cognitive Processing Therapy or Prolonged Exposure) in the past 3 months or are currently receiving an evidence-based PTSD treatment\n* They have an intellectual disability or significant cognitive impairment that would prevent them from engaging fully in treatment\n* They are currently on any blood-thinning medications or have a coagulopathy -They have any of the following conditions: a recent myocardial infarction, glaucoma, a pre- existing contralateral nerve palsy, severe emphysema, or a cardiac conduction blockade.\n* They are allergic to any of the medications injected (i.e., ropivacaine, lidocaine, propofol)\n* They have an active infection\n* They have a serious or unstable medical illness or instability for which hospitalization may be likely within the next year\n* They have a visual or auditory impairment that would prevent them from fully participating in study activities\n* They are involved with current legal actions related to the traumatic event that is anticipated to be targeted during treatment\n* They have substance dependence that, in the judgment of the Principal Investigator, may require hospitalization if substances were discontinued.\n* Subjects who, at the time of consent, appear to have extenuating life circumstances (e.g., unstable housing, no internet access, etc.) which, in the judgment of the Principal Investigator, could affect the ability to deliver the intervention with fidelity",{"count":377,"type":21},270,[379],"EARLY_PHASE1","The purpose of this study is to understand if we can improve the treatment for posttraumatic stress disorder (PTSD). We are looking into whether the combination of Stellate Ganglion Block (SGB) treatment and Cognitive Processing Therapy (CPT) can reduce symptoms of PTSD. CPT is a trauma-focused talk therapy that can help identify and challenge unhelpful trauma-related beliefs about oneself, others, and the world. It is known to be a highly effective talk therapy for PTSD. SGB treatment is a procedure involving an injection of local anesthetic into a bundle of nerves located in the neck that is part of the sympathetic nervous system which controls our body's response to stressful situations and blocks pain.\n\nThe proposed project will systematically test whether combining CPT with SGB produces greater PTSD symptom reductions and functional improvements in the short- and longer-term up to 6-months follow-up compared to CPT (+Placebo) or SGB (+Daily Monitoring) alone.",[28],"2026-05-29",{"date":364,"type":37},{"date":92,"type":37},{"date":386,"type":21},"2029-12-31",{"name":388,"class":44},"Rush University Medical Center",{"id":390,"slug":4,"hasResults":11,"nctId":391,"briefTitle":392,"officialTitle":392,"acronym":4,"eligibilityCriteria":393,"healthyVolunteers":11,"sex":52,"minAge":18,"maxAge":394,"enrollmentInfo":395,"targetDuration":4,"studyType":22,"phases":397,"briefSummary":399,"conditions":400,"keywords":402,"overallStatus":174,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":406,"completionDateStruct":407,"leadSponsor":409,"locationsCount":209},"100576686","NCT06788522","The Effects of Orexin Antagonism on Fear Extinction in PTSD","Inclusion Criteria:\n\n* (same for Phase 1 and Phase 2):\n\n  * men and women\n  * a history of US military service\n  * capable of reading and understanding English\n  * able to provide written informed consent\n* Criterion A event meets DSM-5 criteria and occurred during military service, including combat and military sexual trauma\n* Chronic full PTSD diagnosis \\>3 months duration as indexed by CAPS-5 at screening, and CAPS-5 score \\> 30\n* Insomnia indicated by insomnia severity index (ISI) score \\> 14\n* Subjects on non-exclusionary medications, and must be on a stable dose for at least 4 weeks prior to randomization, including Selective Serotonin Reuptake Inhibitors (SSRIs, e.g.,):\n\n  * sertraline\n  * paroxetine\n  * fluoxetine\n  * fluvoxamine\n  * citalopram\n  * escitalopram\n* Serotonin-norepinephrine reuptake inhibitors (SNRIs; e.g.):\n\n  * Desvenlafaxine\n  * Duloxetine\n  * Levomilnacipran\n  * Venlafaxine\n* For subjects who are in psychotherapy, treatment must be stable for 6 weeks\n* Women of child-bearing potential must not be pregnant or have plans for pregnancy or breastfeeding during the study and must use a medically acceptable method of birth control\n\nExclusion Criteria:\n\n* Moderate or severe DSM-5 alcohol or cannabis use disorder in the last 3 months\n\n  * Mild alcohol use disorder with abstinence of 30 days will be allowed\n  * Mild marijuana use disorder will be allowed with abstinence for one week prior to participation\n  * Any other DSM-5 drug use disorder in the last 3 months will be excluded\n* Lifetime bipolar disorder I or II, schizophrenia, schizoaffective disorder, obsessive-compulsive disorder, or major depressive disorder with psychotic features\n* Exposure to trauma in the last 3 months\n* Use of exclusionary antidepressant (trazodone, mirtazapine, doxepin, tricyclics), mood stabilizers (e.g., lithium), antipsychotic medication\n* Prominent suicidal or homicidal ideation or any suicidal behavior in the past 3 months on the Columbia Suicide Severity Rating Scale (C-SSRS) or increased risk of suicide that necessitates additional therapy or inpatient treatment\n* Pre-existing moderate sleep apnea or positive screen for sleep apnea by type III device (AHI\\>15) in the absence of adherence to effective treatment (such as CPAP or oral device)\n* Night shift work or extreme morning or evening tendencies in order to avoid the impact of circadian factors on subjective and objective sleep measures\n* Neurologic disorder or systemic illness affecting CNS function\n* Chronic or unstable medical illness, including:\n\n  * unstable angina\n  * myocardial infarction within the past 6 months\n  * congestive heart failure\n  * preexisting hypotension or orthostatic hypotension\n  * heart block or arrhythmia\n  * chronic renal or hepatic failure\n  * pancreatitis\n  * severe chronic obstructive pulmonary disease\n* History of severe traumatic brain injury as assessed by the Ohio State University Traumatic Brain Injury Identification Method (OSU-TBI ID)\n* Uncorrected hearing impairment\n* Mild cognitive impairment assessed by the Montreal Cognitive Assessment (MOCA)\n* Pregnancy, breastfeeding and\u002For refusal to use effective birth control (for women)\n* Previous adverse reaction to a hypnotic\n* Current use of benzodiazepines, strong inhibitors of CYP3A, or Digoxin\n\n  * The investigators will require that all participants do not consume heavy amounts of alcohol per week (\\>7 drinks for women, \\>14 drinks for men) or use illicit drugs for one week prior to participation","75 Years",{"count":396,"type":21},40120,[398],"PHASE4","PTSD affects approximately 22% of Veterans who have served in Iraq and Afghanistan. Symptoms of PTSD may include re-experiencing, avoidance of trauma reminders, negative thoughts or feelings, and hyperarousal, such as increased startle reactivity and disturbed sleep. Treatments for PTSD are based on fear extinction principles in which individuals are repeatedly exposed a feared cue in the absence of danger, resulting in diminishing physiological reactions, a process believed to underlie recovery from PTSD. Studies suggest that orexin, a wake-promoting neuropeptide, may enhance fear extinction. This study will examine whether suvorexant, a selective orexin-receptor antagonist, will enhance fear extinction in Veterans with PTSD and insomnia. Finding a role for orexins in fear extinction will support the rationale for its further evaluation in the treatment of PTSD. Suvorexant is an accessible, safe medication that has been well-established in treating insomnia. It has outstanding promise for treating common and distressing symptoms in Veterans with PTSD.",[401,28],"Insomnia",[403,28,401],"Fear conditioning","2026-05-28",{"date":364,"type":37},{"date":279,"type":21},{"date":408,"type":21},"2032-06-30",{"name":207,"class":208},{"id":411,"slug":4,"hasResults":11,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":415,"eligibilityCriteria":416,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":417,"enrollmentInfo":418,"targetDuration":4,"studyType":22,"phases":420,"briefSummary":421,"conditions":422,"keywords":423,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":45},"100476657","NCT05486793","Treatment for Antepartum Posttraumatic Stress Disorder\u002FPTSD Study","A Non-Inferiority Trial Testing Delivery of Written Exposure Therapy by Community Health Workers For Treatment of PTSD During Pregnancy","TAPS","Inclusion Criteria:\n\n* Pregnant woman receiving prenatal care at BMC Obstetrics and Gynecology (OB\u002FGYN) Department\n* Presenting for prenatal care prior to gestational age of 28 weeks\n* Meet diagnostic or subthreshold criteria (i.e., endorsement of 3 out of the 4 symptom clusters) for PTSD on the Clinician Administered PTSD Scale for DSM-5 (CAPS-5)\n\nExclusion Criteria:\n\n* Clinician judgment that the patient is not appropriate for outpatient level care (i.e., patient needs detox, inpatient, or residential treatment)\n* Current psychosis or unstable bipolar disorder diagnosis (determined via clinician-administered interview)\n* Currently receiving exposure-based PTSD treatment (e.g., WET, prolonged exposure, cognitive processing therapy) elsewhere\n* Current incarceration. Incarcerated individuals are only seen at BMC for obstetrical care and are not allowed to receive mental health care outside of their correctional facility","50 Years",{"count":419,"type":21},240,[56],"The majority of women with perinatal posttraumatic stress disorder (PTSD) do not receive mental health treatment despite the documented associations between PTSD and adverse pregnancy outcomes; this is likely due to workforce shortages, lack of data on the effectiveness of existing evidence-based treatment for PTSD in usual care obstetrics settings, and patient-level barriers to engagement such as stigma. The proposed study is a randomized controlled trial, which will examine the effectiveness of a brief evidence-based treatment for PTSD (i.e., Written Exposure Therapy) during pregnancy and the non-inferiority of delivery of this treatment by community health workers vs. delivery by mental health clinicians.",[28],[424,425,426,427,428],"Written Exposure Therapy (WET)","Emotion Focused Supportive Therapy (EFST)","Community Health Worker (CHW)","Antepartum care","perinatal mental health","2026-05-26",{"date":404,"type":37},{"date":432,"type":37},"2023-03-01",{"date":434,"type":21},"2027-07-31",{"name":436,"class":44},"Boston University",{"id":438,"slug":4,"hasResults":11,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":4,"eligibilityCriteria":442,"healthyVolunteers":11,"sex":52,"minAge":18,"maxAge":4,"enrollmentInfo":443,"targetDuration":4,"studyType":22,"phases":445,"briefSummary":446,"conditions":447,"keywords":448,"overallStatus":174,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":453,"completionDateStruct":454,"leadSponsor":456,"locationsCount":45},"100618478","NCT07332143","Psilocybin-Assisted Therapy","The Safety and Acceptability of Psilocybin With Support and With Massed Prolonged Exposure Therapy for PTSD","Eligible participants must be over the age of 18. They must self-identify as Georgia military veterans, reservists, National Guard members, or active-duty service members. Additionally, they must be seeking treatment for PTSD, which will be confirmed by a CAPS-5-R assessment. The criteria below will be applicable to all participants, regardless of study treatment arm.\n\nInclusion Criteria\n\n1. Meet criteria for PTSD due to trauma occurring at least 6 months prior based on CAPS-5-R diagnostic scoring rules.\n2. Willingness of participant to sign a release for the investigators to communicate with their primary care or mental health providers, if indicated\n3. Are 18 years and older.\n4. Are able to visually read and understand the English language and give written informed consent.\n5. Are able to swallow pills.\n6. Agree to have study visits video and\u002For audio recorded, including dosing session, Independent Rater assessments, and non-drug psychotherapy sessions.\n7. Must provide a contact (relative, spouse, close friend, or other support person) who is willing and able to be reached by the investigators in the event of a participant becoming suicidal or unreachable.\n8. Must agree to inform the investigators within 48 hours of any medical conditions and procedures.\n9. If able to become pregnant, must have a negative pregnancy test prior to study entry, at study entry, and prior to the psilocybin Session. They must agree to use highly effective birth control for a month prior to the psilocybin session and through 10 days after the Medicine session. Highly effective birth control methods include intrauterine device, injected, implanted, intravaginal, or transdermal hormonal methods, abstinence, oral hormones plus a barrier contraception, vasectomized sole partner, or double barrier contraception. Two forms of contraception are required with any barrier method or oral hormones (i.e., condom plus diaphragm, condom or diaphragm plus spermicide, oral hormonal contraceptives plus spermicide or condom). Not able to become pregnant is defined as permanent sterilization, postmenopausal (i.e., 12 consecutive months without menstruation), or assigned male at birth.\n10. Agree to the following lifestyle modifications: comply with requirements for fasting and refraining from certain medications prior to the psilocybin Session, not participate in any other interventional clinical trials during the duration of the treatment, and be accompanied to hotel after Medicine Session, and commit to medication dosing, therapy, and study procedures.\n\nExclusion Criteria\n\nPotential participants are ineligible to enroll in the protocol if they:\n\n1. Are not able to give adequate informed consent.\n2. Are currently engaged in compensation litigation whereby financial gain would be achieved from prolonged symptoms of PTSD or any other psychiatric disorders. \"Compensation litigation\" will not include veterans who are service connected through PTSD or other conditions.\n3. Are likely, in the investigator's opinion and via observation during the Preparatory Period, to be re-exposed to their index trauma or other significant trauma, lack social support, or lack a stable living situation.\n4. Have any current problem which, in the opinion of the investigator or Medical Monitor, might interfere with participation.\n5. Have a family history bipolar disorder type 1 or a psychotic disorder in first degree relatives.\n6. Have a history of or current bipolar type 1 disorder, or primary psychotic disorder (e.g., schizophrenia), as assessed via DIAMOND and clinical interview, dementia; or intellectual disability.\n7. Have current major depressive disorder with psychotic features assessed via DIAMOND.\n8. Have met criteria at any time during their life for hallucinogen substance use disorder.\n9. Meet criteria for current (past 3 months) moderate or severe substance use disorder, as defined by 4 or more DSM SUD criteria symptoms.\n10. Have a positive screen for cocaine or amphetamines on drug test administered in local community or on site unless being taken as prescribed by a physician.\n11. Have current clinically relevant personality pathology.\n12. Any participant presenting current serious suicide risk, as determined through psychiatric interview, responses to C-SSRS, and clinical judgment of the investigator will be excluded; however, history of suicide attempts is not an exclusion. Any participant who is likely to require hospitalization related to suicidal ideation and behavior, in the judgment of the investigator, will not be enrolled. Any participant presenting with the following on the C-SSRS administered at screening or baseline will be excluded:\n\n    1. Suicidal ideation score of 4 or greater within the last six months.\n    2. Any suicidal behavior, including suicide attempts or preparatory acts, within the last 6 months of the assessment\n13. Require ongoing concomitant therapy with a psychiatric medication with exceptions described in protocol section on Concomitant Medications.\n14. Other medical exclusion criteria specified in the protocol",{"count":444,"type":21},150,[24],"This pilot study will examine the safety, tolerability, acceptability, and efficacy of combination psilocybin + psychotherapy to decrease PTSD symptoms. Participants will be randomized into two different treatment groups, allowing the investigators to directly compare PE augmented with psilocybin and psilocybin-assisted psychotherapy.",[28],[131,28,449,450],"Supportive therapy","PE therapy","2026-05-21",{"date":429,"type":37},{"date":137,"type":21},{"date":455,"type":21},"2027-03",{"name":457,"class":44},"Emory University",{"id":459,"slug":4,"hasResults":11,"nctId":460,"briefTitle":461,"officialTitle":461,"acronym":462,"eligibilityCriteria":463,"healthyVolunteers":11,"sex":52,"minAge":18,"maxAge":464,"enrollmentInfo":465,"targetDuration":4,"studyType":22,"phases":467,"briefSummary":468,"conditions":469,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":45},"100631877","NCT07506395","Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder","GPAT","Inclusion Criteria:\n\nGeneral:\n\n-T+H years of age and \\\u003C89 years of age\n\nIdentify as a member of one of the cohorts to be studied:\n\n* Veteran or first responder\n* Female survivor of sexual violence\n* Indigenous person\n* Not pregnant, planning to become pregnant, or breastfeeding; if able to become pregnant, willing to use reliable form of birth control for the duration of the study\n* If needed, ability and willingness to taper and discontinue medications that may interfere with the action of psilocybin\n* Ability to read, speak, and understand English\n* Ability and willingness to consent to the terms of the study, including attending all trial visits (most of which will occur in a group setting), preparation and\n* follow-up sessions, and completing all trial evaluations\n* Ability and willingness to swallow capsules\n\nPTSD severity:\n\n* Meet criteria for PTSD, as defined in the DSM-5\n* At screening, symptoms of moderate to severe PTSD (PCL-5 score of 34 or greater) present for at least six months\n\nExclusion Criteria:\n\n* Inability to achieve five days of abstinence from alcohol, non-prescribed opioids, methamphetamines, cocaine, benzodiazepines, or other illicit substances\n* Inability or unwillingness to remain abstinent from cannabis use for 24 hours prior to psilocybin dosing session and 12 hours after receiving the dose of psilocybin\n* Risk for clinically significant acute withdrawal from any substance that would cause safety concern on the day of dosing\n* Any medical condition that would preclude safe participation in the study, including the following, as determined by medical history review, physical examination, electrocardiogram (ECG), and clinical laboratory tests: Pregnancy\u002Fbreastfeeding\n\nCardiovascular conditions:\n\n* Uncontrolled hypertension, defined as \\>140\u002F90 mm Hg at screening or baseline or \\>145\u002F95 mm Hg on presentation for dosing day assessed on three consecutive blood pressure measurements\n* History of myocardial infarction, cardiac ischemia, congestive heart failure, clinically relevant valvular heart disease, or pulmonary hypertension; any other significant history of cardiovascular condition, based on the clinical judgment of the Trial Physician, which would make a participant unsuitable for the trial\n* ECG: Clinically significant abnormality (e.g. atrial fibrillation based on judgement of trial physician including prolonged corrected QT interval (QTc\\> 450 milliseconds (males) or \\>470 milliseconds (females)\n* Poorly controlled diabetes (HbA1c \\>8.0%; clinically significant hypoglycemia in the past 6 months)\n* Neurological conditions (e.g. epilepsy or other seizure disorder) or neurodegenerative disease (e.g., dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis.), or brain tumor that would impact participation in the trial Serious abnormalities of complete blood count or chemistry\n\n  * Severe hepatic impairment\n  * Severe renal impairment,\n  * Unstable existing thyroid disorder\n* Any of the following psychiatric conditions:\n\n  * Active suicidal ideation; history of hospitalization for suicide attempt within the 12 months prior to screening, affirmative responses to C-SSRS questions 4 or 5\n  * Confirmed diagnosis of schizophrenia or other psychotic disorder, firstdegree relative with schizophrenia\n  * Axis-II diagnosis\n* Use of psychedelics (e.g., psilocybin, mescaline, ayahuasca, DMT, LSD, MDMA, or ketamine) resulting in a discrete psychedelic experience in the past six months.\n\nUsing daily dose of psilocybin mushrooms at dose \\\u003C0.2 mg or LSD at \\\u003C20 mcg per day for \\\u003C30 days in a year (\"microdosing\") will not be an exclusion criterion.\n\nHowever, participants must agree to no further use of psychedelics during this study starting at screening.\n\n* Returning to an unsafe environment and\u002For inadequate social support-Any other condition, physical or psychological symptom, medication, or other relevant finding prior to randomization that, based on the clinical judgment of trial personnel, would make a participant unsuitable for the trial.-\n* Participation in experimental treatment for PTSD or any research studies within 30 days of screening assessment","89 Years",{"count":466,"type":21},36,[170],"This study is a community-informed, pragmatic, open-label, phase 1 clinical trial of group-format psilocybin-assisted therapy (GPAT) for individuals with post-traumatic stress disorder (PTSD). The primary objectives of this phase 1 study are to assess the safety and feasibility of (GPAT) for individuals with (PTSD) and to evaluate preliminary effects on PTSD severity.",[28],"2026-05-20",{"date":472,"type":37},"2026-05-22",{"date":474,"type":37},"2026-05-01",{"date":476,"type":21},"2028-05-01",{"name":478,"class":44},"University of New Mexico",{"id":480,"slug":4,"hasResults":11,"nctId":481,"briefTitle":482,"officialTitle":482,"acronym":4,"eligibilityCriteria":483,"healthyVolunteers":11,"sex":52,"minAge":484,"maxAge":217,"enrollmentInfo":485,"targetDuration":4,"studyType":22,"phases":486,"briefSummary":487,"conditions":488,"keywords":489,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":497,"leadSponsor":499,"locationsCount":501},"100622359","NCT07382596","Cervical Plexus Hydrodissection With D5W Versus NS for Treatment-Resistant PTSD","Inclusion Criteria:\n\n* Inclusion Criteria:\n* Not involved in another study of PTSD treatment\n* Reliable transportation\n* Comfortable with computers\n* Tried 2 or more medications for treatment of PTSD symptoms\n* Tried 2 or more non-medication treatments for PTSD symptom\n* No known life-threatening illness\n* Not taking daily narcotics\n* Not having 3 or more alcoholic drinks on an average day\n* No active suicidal plans\n* No major surgery plans\n* No major life stress that might interfere with completing study\n* Symptoms for more than 1 year\n* Not planning to move for next 18 months.\n* Living within an hour of Portland, OR, Madison, WI, or Lexington, KY\n* Wiling to provide 2 email and 2 phone contact methods\n* Willing to answer questions on multiple occasions over the course of a year.\n* Willing to be assigned to 3 months of usual care treatment\n* No diagnosis of schizophrenia, Borderline Personality Disorder, or Bipolar Disorder.\n* No severe needle phobia\n* Chronic pain ≤ 5\u002F10\n* PCL-C score ≥ 50\n\nExclusion Criteria:\n\n\\-","19 Years",{"count":149,"type":21},[398],"PTSD is a chronic mental health condition that drastically reduces an individual's quality of life Dextrose injection with a small needle has been used for chronic pain patients and observational results have shown it to be effective in reducing anxiety, brain fog, and depression in patients with PTSD. This randomized trial will compare dextrose injection with an injection control of normal saline (NS)",[28],[490,491,492],"Dextrose","Hydrodissection","Cervical Plexus","2026-05-16",{"date":495,"type":37},"2026-05-19",{"date":493,"type":37},{"date":498,"type":21},"2030-04-01",{"name":500,"class":44},"Dr. Dean Reeves Clinic",4,{"id":503,"slug":4,"hasResults":11,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":507,"eligibilityCriteria":508,"healthyVolunteers":11,"sex":52,"minAge":509,"maxAge":18,"enrollmentInfo":510,"targetDuration":4,"studyType":22,"phases":512,"briefSummary":513,"conditions":514,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":526,"locationsCount":45},"100541508","NCT06330779","Trauma-adapted Yoga in Child & Adolescent Psychiatry.","Trauma-adapted Yoga in Child & Adolescent Psychiatry: A Multicenter Study.","TAY-CAP","Inclusion Criteria:\n\n* Adolescents who have received a diagnosis (not under evaluation) of PTSD and\u002For ADHD\n* Understanding English or Swedish languages.\n\nExclusion Criteria:\n\n* Ongoing substance use,\n* active manic periods,\n* psychotic disorders,\n* suicidality,\n* cognitive impairment.\n* serious physical illness prohibiting participation in physical activities.","12 Years",{"count":511,"type":21},180,[56],"The goal of this randomized clinical trial is to evaluate the efficacy of trauma-adapted yoga as a complementary intervention to care as usual in child and adolescents psychiatry clinics, in the population of adolescents with the diagnosis of ADHD and\u002For PTSD. We hypothesize that trauma-adapted yoga (TAY) is an effective non-pharmacological intervention for adolescent with ADHD and\u002For PTSD. Aims: (1) Validate the impact of TAY on the mental health \\& quality of life of adolescents with ADHD and\u002For PTSD. (2) Investigate the feasibility of online TAY for continued self-care. (3) Explore adolescents' experiences \\& parental perspectives on TAY in their treatment. (4) Explore healthcare professionals' experience on the integration of TAY into clinical practice.\n\nWithin and between group (yoga group vs waiting list) analyses will be performed.",[515,28,516,517,518,519],"ADHD","Quality of Life","Self-Control","Pain","Affect","2026-05-15",{"date":495,"type":37},{"date":523,"type":37},"2025-02-01",{"date":525,"type":21},"2028-12-31",{"name":527,"class":44},"University West, Sweden",{"id":529,"slug":4,"hasResults":11,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":533,"eligibilityCriteria":534,"healthyVolunteers":11,"sex":52,"minAge":18,"maxAge":4,"enrollmentInfo":535,"targetDuration":4,"studyType":22,"phases":537,"briefSummary":539,"conditions":540,"keywords":544,"overallStatus":174,"whyStopped":4,"lastUpdateSubmitDate":547,"lastUpdatePostDateStruct":548,"startDateStruct":550,"completionDateStruct":552,"leadSponsor":554,"locationsCount":4},"100636820","NCT07570654","Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder","A Phase 2b\u002F3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder","Redefine","Inclusion Criteria:\n\n* 18 years or older\n* Diagnosed with PTSD at least 6 months ago\n\nExclusion Criteria:\n\n\\- Diagnosed with certain psychiatric conditions such as bipolar disorder, schizophrenia, OCD, anorexia, or other conditions",{"count":536,"type":21},300,[24,538],"PHASE3","The Redefine Study (COMP202) is testing COMP360 to see if it may reduce post-traumatic stress disorder (PTSD) symptoms when administered alongside monitoring and support from a trained study team. COMP360 is a lab-made form of the naturally occurring chemical compound psilocybin.",[541,28,542,543],"PTSD - Post Traumatic Stress Disorder","PTSD Symptoms","PTSD, Post Traumatic Stress Disorder",[545,31,533,28,546],"COMP360","trauma","2026-05-08",{"date":549,"type":37},"2026-05-12",{"date":551,"type":21},"2026-09",{"date":553,"type":21},"2029-09",{"name":555,"class":284},"COMPASS Pathways",{"id":557,"slug":4,"hasResults":11,"nctId":558,"briefTitle":559,"officialTitle":560,"acronym":561,"eligibilityCriteria":562,"healthyVolunteers":11,"sex":52,"minAge":18,"maxAge":4,"enrollmentInfo":563,"targetDuration":4,"studyType":22,"phases":565,"briefSummary":566,"conditions":567,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":569,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":45},"100420275","NCT04752618","Safe Mothers, Safe Children Initiative","Treating Maternal PTSD to Enhance and Reduce Maltreatment Recidivism: Safe Mothers, Safe Children","SMSC","Inclusion Criteria (mothers):\n\n* Receiving preventive services at the time of the consent session to participate in the study\n* Meeting a severity score of 28 or higher OR probable DSM-5 diagnostic criteria for PTSD (PDS-5)\n* Having 1-10-year-old child\n* Being the legal guardian for the child with physical and legal custody\n* Being able to read, write, and speak English or Spanish\n\nExclusion Criteria (mothers):\n\n* Having suicidal ideation present in the past month prior to pre-assessment or reports of a suicide attempt in the past year (SCID-5)\n* Meeting a diagnosis of severe substance or alcohol use disorder (≥ 6 symptoms on SCID) AND not in early remission (≥3 months without meeting any substance or alcohol use disorder criteria (except craving)\n* Having current or active symptoms of psychosis in the past month\n* Having a disability affecting communication, such as deafness\n* Having an index child with a developmental condition that impedes cognitive and\u002For physical functioning, e.g. autism\n* Having an index child with current symptoms or diagnosis of psychosis as defined by the DSM-5 in the past 3 months\n* Experiencing current or history of intimate partner violence (IPV) or family violence:\n\nIf there is a history of IPV\u002Ffamily violence and the relationship is no longer active, the relationship must have ended for at least ninety days with no intention of restarting; If there is a history of IPV\u002Ffamily violence, but the relationship is ongoing, there must not have been an IPV\u002Ffamily violence event for at least one year\n\nInclusion criteria (clinicians):\n\n\\- Must be a currently or formerly hired Study Clinician or Clinical Director with Safe Mothers, Safe Children.\n\nExclusion criteria (clinicians):\n\n\\- There are no exclusion criteria for this population. Participants in this population will cease completion of therapist-copy measures upon the conclusion of their role with Safe Mothers, Safe Children, or upon withdrawal from participation in these measures.",{"count":564,"type":21},160,[56],"The purpose of this study is to assess the efficacy of the combined interventions, Skills Training in Affective and Interpersonal Regulation (STAIR) and Parent-Child Interaction Therapy (PCIT) or P-STAIR, for treating maternal PTSD and reducing maltreatment recidivism.",[28,197,568],"Child Maltreatment",{"date":570,"type":37},"2026-05-07",{"date":572,"type":37},"2021-05-01",{"date":574,"type":21},"2027-04-30",{"name":330,"class":44},{"id":577,"slug":4,"hasResults":11,"nctId":578,"briefTitle":579,"officialTitle":579,"acronym":4,"eligibilityCriteria":580,"healthyVolunteers":166,"sex":52,"minAge":18,"maxAge":147,"enrollmentInfo":581,"targetDuration":4,"studyType":22,"phases":583,"briefSummary":584,"conditions":585,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":587,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":593,"locationsCount":45},"100467608","NCT05368987","Neuromodulation of the Fear Extinction Circuit Using Temporally and Anatomically Specific TMS in Humans","Inclusion Criteria:\n\n* Willing and able to provide informed consent.\n* Inclusion Criteria for PTSD Subjects - Diagnosis of current PTSD\n* Inclusion Criteria: Healthy Controls (HC) - no current psychiatric disorders (\"Axis I\" disorders)\n\nExclusion Criteria:\n\n* Lifetime history of seizure or significant head trauma or other significant neurologic disease (e.g., tic disorder)\n* History of serious\u002Fsignificant psychiatric diagnoses (\"Axis I\" diagnoses)\n* Current significant suicidal ideation, plan or intent or suicidal behavior in past 6 months based on CSSRS and clinical judgment or Self-injurious behavior that involves suicidal intent, requires medical attention, or occurs daily\n* Use of neuroleptics within one year prior to study\n* Current substance use\n* Pregnancy (to be ruled out by urine β-HCG).\n* Metallic implants or devices contraindicating magnetic resonance imaging.\n* Currently taking medications that lower the seizure threshold. These include antipsychotics, high dose theophylline or stimulants such as methylphenidate. Patients taking bupropion must be on a stable dose (\\*last 3 months) and take less than or equal to 300 mg\u002Fday.\n* Implanted devices in subject's head (shunts, cochlear implants); metal in subject's head (other than dental implants).\n* High risk of adverse emotional or behavioral reaction, and\u002For an inability to understand study procedures or the informed consent process\n* Additional exclusion criteria for Healthy controls (HC) group: Current psychiatric diagnosis (\"Axis I\" diagnosis)",{"count":582,"type":21},250,[56],"This study aims to explore the mechanisms of how transcranial magnetic stimulation (TMS) impacts fear circuits. The overarching objectives are to understand how varying TMS parameters affect targeted brain regions in order to optimize its impact on enhancing fear extinction memory consolidation in a population with known fear extinction deficiencies: post-traumatic stress disorder (PTSD). 250 subjects will take part in this research study across UTHealth Houston. The study will include preliminary screenings, baseline visits, and experimental visits across four days",[28],"2026-04-30",{"date":588,"type":37},"2026-05-05",{"date":590,"type":37},"2022-02-01",{"date":592,"type":21},"2028-09-30",{"name":594,"class":44},"The University of Texas Health Science Center, Houston",""]